文献速递湿疹皮炎与荨麻疹

口服JAK1抑制剂Abrocitinib治疗特应性皮炎的2b期随机临床试验

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
PubMed 文献 · JAMA Dermatol · 2019-01-01

这项2b期随机双盲安慰剂对照试验纳入267例中重度特应性皮炎成人患者,评估每日一次口服Abrocitinib(200mg、100mg、30mg、10mg)或安慰剂的疗效与安全性。结果显示200mg和100mg组在第12周IGA应答率及EASI改善均显著优于安慰剂,不良事件常见但总体耐受良好。

要点

  • Abrocitinib 200mg和100mg每日一次可显著改善中重度特应性皮炎的体征和症状。
  • 第12周IGA应答率200mg组43.8%、100mg组29.6%,安慰剂组5.8%。
  • 最常见不良事件为特应性皮炎、上呼吸道感染、头痛、恶心和腹泻。

核心结论

  • 每日一次口服Abrocitinib对成人中重度特应性皮炎的短期治疗有效且耐受良好。

研究设计与样本

  • 2b期随机双盲安慰剂对照平行组试验,2016年4月15日至2017年4月4日在5国58个中心进行。
  • 纳入267例18至75岁、临床诊断中重度特应性皮炎至少1年且外用药物应答不足或禁忌的患者。
  • 患者按1:1:1:1:1随机接受Abrocitinib 200mg、100mg、30mg、10mg或安慰剂每日一次治疗12周。

主要发现

  • 第12周IGA达清除或几乎清除且较基线改善≥2级的比例:200mg组43.8%(21/48,P<.001),100mg组29.6%(16/54,P<.001),安慰剂组5.8%(3/52)。
  • 模型估计IGA应答率:200mg组44.5%(95%CI 26.7%-62.3%),100mg组27.8%(95%CI 14.8%-40.9%),安慰剂组6.3%(95%CI -0.2%至12.9%)。
  • 第12周EASI较基线百分比变化:200mg组82.6%(90%CI 72.4%-92.8%,P<.001),100mg组59.0%(90%CI 48.8%-69.3%,P=.009),安慰剂组35.2%(90%CI 24.4%-46.1%)。
  • 267例中184例(68.9%)报告不良事件,最常见(任一组≥3例)为特应性皮炎、上呼吸道感染、头痛、恶心和腹泻。
  • 观察到剂量依赖性血小板计数下降,但第4周后呈向基线回升趋势。

临床怎么用

  • 对于外用治疗应答不足或禁忌的中重度特应性皮炎成人患者,可考虑每日一次口服Abrocitinib 200mg或100mg作为短期治疗选择。
  • 治疗期间需监测血小板计数,关注剂量依赖性下降及回升趋势。

局限性

  • 研究仅评估12周短期疗效和安全性,长期疗效与安全性需进一步试验。
  • 样本量有限,纳入人群为18至75岁成人,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Atopic dermatitis is associated with substantial patient and caregiver burden. Currently available treatments for atopic dermatitis are inadequate or contraindicated for some patients. Abrocitinib (PF-04965842) is an oral Janus kinase 1 selective inhibitor under investigation for the treatment of atopic dermatitis. OBJECTIVE: To investigate the efficacy and safety of abrocitinib for patients with moderate to severe atopic dermatitis. DESIGN, SETTING, AND PARTICIPANTS: A phase 2b, randomized, double-blinded, placebo-controlled, parallel-group trial was conducted from April 15, 2016, to April 4, 2017, at 58 centers in Australia, Canada, Germany, Hungary, and the United States among 267 patients 18 to 75 years of age with a clinical diagnosis of moderate to severe atopic dermatitis for 1 year or more and inadequate response or contraindication to topical medications for 4 weeks or more within 12 months. Efficacy was assessed in the full analysis set, which was a modified intention-to-treat population that included all patients who received 1 dose or more of the study drug except for 4 patients from 1 site. INTERVENTIONS: Participants were randomly assigned 1:1:1:1:1 to receive abrocitinib (200 mg, 100 mg, 30 mg, or 10 mg) or placebo once daily for 12 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of patients achieving an Investigator's Global Assessment of clear (0) or almost clear (1) with an improvement from baseline of 2 grades or more at week 12. The secondary outcome was the percentage change from baseline in the Eczema Area and Severity Index at week 12. RESULTS: Of the 267 participants, 144 were women (mean [SD] age, 40.8 [16.1] years). At week 12, 21 of 48 patients receiving 200 mg of abrocitinib (43.8%; P < .001, 2-sided), 16 of 54 patients receiving 100 mg of abrocitinib (29.6%; P < .001), and 3 of 52 patients receiving placebo (5.8%) achieved grades of clear or almost clear on the Investigator's Global Assessment scale with improvement of 2 grades or more; these rates correspond to maximum effect model-based estimates of 44.5% (95% CI, 26.7%-62.3%) for those receiving 200 mg of abrocitinib, 27.8% (95% CI, 14.8%-40.9%) for those receiving 100 mg of abrocitinib, and 6.3% (95% CI, -0.2% to 12.9%) for those receiving placebo. Reductions in the Eczema Area and Severity Index were 82.6% (90% CI, 72.4%-92.8%; P < .001) for those receiving 200 mg of abrocitinib, 59.0% (90% CI, 48.8%-69.3%; P = .009) for those receiving 100 mg of abrocitinib, and 35.2% (90% CI, 24.4%-46.1%) for those receiving placebo. Adverse events were observed in 184 of 267 patients (68.9%); the most frequently reported adverse events (in ≥3 patients in any group) were dermatitis atopic, upper respiratory tract infection, headache, nausea, and diarrhea. Dose-dependent decreases in platelet count were observed but trended upward toward baseline levels after week 4. CONCLUSIONS AND RELEVANCE: Once-daily oral abrocitinib was effective and well tolerated for short-term use in adults with moderate to severe atopic dermatitis. Additional trials are necessary to evaluate long-term efficacy and safety. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02780167.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial. JAMA Dermatol. 2019. PMID: 31577341. doi:10.1001/jamadermatol.2019.2855

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。